|
Myocardial Infarction
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: a Mendelian randomization meta-analysis.
|
24695040 |
2014 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A case-control association study on 229 Myocardial Infarction (MI) patients and 217 healthy controls was carried out to determine the role of tissue-plasminogen activator (t-PA) (Alu-repeat insertion (I)/deletion (D)) and plasminogen activator inhibitor (PAI-1) (4G/5G insertion/deletion) polymorphisms with MI in the Pakistani population.
|
21082259 |
2011 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of macrophage-derived urokinase plasminogen activator in myocardial infarct repair: urokinase attenuates ventricular remodeling.
|
20380835 |
2010 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) has already been associated with atherosclerosis; myocardial infarction; and cardiovascular disease risk factors such as obesity, insulin resistance, and dyslipidemia.
|
20127289 |
2010 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A case control study was conducted to test the hypothesis that plasminogen activator inhibitor type-1 (PAI-1) 4G/5G gene polymorphism confers an increased risk for myocardial infarction (MI) in patients with known coronary atherosclerosis.
|
17721742 |
2008 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A plasminogen gene SNP was associated with MI risk.
|
17927806 |
2008 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
A plasminogen gene SNP was associated with MI risk.
|
17927806 |
2008 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study.
|
17656673 |
2007 |
|
Myocardial Infarction
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke.
|
17161063 |
2006 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
None of the 9 polymorphisms of genes encoding proteins involved in coagulation (G-455A beta-fibrinogen: OR, 1.0; CI, 0.8 to 1.2; G1691A factor V: OR, 1.1; CI, 0.6 to 2.1; G20210A factor II: OR, 1.0; CI, 0.5 to 1.9; and G10976A factor VII: OR, 1.0; CI, 0.8 to 1.3), platelet function (C807T glycoprotein Ia: OR, 1.1; CI, 0.9 to 1.3; and C1565T glycoprotein IIIa: OR, 0.9; CI, 0.8 to 1.2), fibrinolysis (G185T factor XIII: OR, 1.2; CI, 0.9 to 1.6; and 4G/5G plasminogen activator inhibitor type 1: OR, 0.9; CI, 0.7 to 1.2), or homocysteine metabolism (C677T methylenetetrahydrofolate reductase: OR, 0.9; CI, 0.8 to 1.1) were associated with an increased or decreased risk of myocardial infarction.
|
12615788 |
2003 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Determination of the genotypes of the connexin 37, plasminogen-activator inhibitor type 1, and stromelysin-1 genes may prove reliable in predicting the genetic risk of myocardial infarction and might thus contribute to the primary prevention of this condition.
|
12477941 |
2002 |
|
Myocardial Infarction
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hemostatic and fibrinolytic parameters in survivors of myocardial infarction: a low plasma level of plasmin-alpha2-antiplasmin complex is an independent predictor of coronary re-events.
|
11229822 |
2001 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Disturbances in fibrinolytic activity, such as increase in plasminogen activator inhibitor (PAI) activity, have been linked with an increased risk for coronary artery disease (CAD) and myocardial infarction (MI).
|
10494775 |
1999 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) is a major physiological inhibitor of fibrinolysis, with its plasma levels correlating with the risk for myocardial infarction and venous thrombosis.
|
10073956 |
1999 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The 4G allele of the plasminogen activator inhibitor gene (P < 0.05) and the PlA2 allele of the glycoprotein IIIa gene (P < 0.01) were associated with an increased risk of MI in our study population.
|
9700201 |
1998 |
|
Myocardial Infarction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Platelet glycoprotein IIb/IIIa may be involved in the pathogenesis of myocardial infarction as the key element in platelet aggregation and as the binding site of lipoprotein(a) to platelets, inhibiting plasminogen binding and activation.
|
9733226 |
1998 |